SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers

Study Number

3808823

Phase

Age Group

Adult

Principal Investigator

Purpose

This is a randomized Phase II study of standard of care (SOC) chemotherapy monotherapy vs. SOC chemotherapy combined with tocilizumab in in Black and non-Black patients with metastatic triple negative or ER low breast cancer.

Check your eligibility for this trial

Check now

Full Title

A Pragmatic Phase II Trial of Chemotherapy +/- Tocilizumab for Metastatic Triple Negative and ER-low Breast Cancers

ClinicalTrials.Gov ID

NCT05846789

Get more information and eligibility criteria for this trial at ClinicalTrials.gov

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.